Quantcast

Latest Cancer vaccine Stories

2014-09-11 08:27:28

-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in...

2014-09-08 16:25:31

The Encore at Wynn Las Vegas: September 11th, 2014 ZUG, Switzerland and NEW YORK, Sept. 8, 2014 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various indications in cancer and the central nervous system (CNS), including orphan indications, today announced that Dr. Angelos M. Stergiou, Chief Executive Officer and Chairman of the Board of SELLAS, will...

2014-09-05 20:21:03

Horses with melanoma are the subject of this major clinical study TAMPA, Fla., Sept. 5, 2014 /PRNewswire/ -- Morphogenesis Inc., the biotechnology firm developing ImmuneFx(TM), a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri. Pat Lawman, PhD., co-founder and CEO of Morphogenesis...

2014-09-04 16:27:07

Unique Multivalent WT1 Vaccine to be developed across hematological malignancies and solid tumors NEW YORK, Sept. 4, 2014 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company today announced that it has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSK's proprietary WT1 cancer vaccine. "This...

2014-08-28 12:29:01

Key Program Part of Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 28, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has made significant progress related to the development of its lead antibody program designated 5B1. The fully-human antibody was recovered using the Company's internally developed antibody discovery platform. These...

2014-08-28 08:27:53

WHITE PLAINS, N.Y., Aug. 28, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) and OncoPep have entered a partnership to advance an experimental cancer vaccine to treat patients with smoldering multiple myeloma (SMM), an asymptomatic stage of myeloma. The partnership is through LLS's Therapy Acceleration Program® (TAP), through which LLS forges collaborations with biotechnology companies to help bring therapies to patients faster. OncoPep is developing a...

2014-08-25 12:26:05

Contract Results from Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the...

2014-08-25 08:27:12

Initial Closing is for $10 Million FREDERICK, Md., Aug. 25, 2014 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement of $80 million of units and common stock. Vaccinogen received gross proceeds of $10 million in this first closing. http://photos.prnewswire.com/prnvar/20140825/139089 Vaccinogen is preparing to start ACTIVE, a confirmatory Phase IIIb pivotal...

2014-08-12 23:04:31

MicroVAX, LLC, National Cancer Center (NCC), Singapore, and Singapore Clinical Research Institute (SCRI) joint media release, August 12, 2014 Manassas, Virginia (PRWEB) August 12, 2014 MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the breast, prostate, colon, ovary and lung, that have...

2014-08-11 08:28:16

TAMPA, Fla., Aug. 11, 2014 /PRNewswire/ -- Morphogenesis Inc., the Tampa-based biotech company that developed the ImmuneFx(TM) cancer vaccine for dogs, cats and horses, announces that it has chosen Florida Veterinary Referral Center & 24-Hour Emergency Hospital in Estero, FL, as the newest exclusive provider of the ImmuneFx(TM) therapy process for companion animals. ImmuneFx(TM) primes and educates the pet's own immune system to recognize and kill cancer cells without harming...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related